United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis
(NASDAQ:UTHR) SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its TETON-2 stud...
How does Tyvaso®'s efficacy and safety profile compare to existing and pipeline IPF therapies, and what market share could it realistically capture?
What is the anticipated timeline for regulatory approval and market launch of Tyvaso® for IPF, and what milestones remain?
How will the positive TETON-2 results influence United Therapeutics' short‑term stock price and trading volume?
13 days ago